+ Watch EPOC
on My Watchlist
Undervalued based on assets.
Huge potential for future revenue, but so far untapped. 2013-2014 things should pick up as they capitalize on their user base of 50% of US physicians, the most valuable customers in the world.
**Physicians love Epocrates' mobile applications, because they reduce prescription errors, improve patient care, and save time.**Epocrates is disrupting the face-to-face sales model used by pharma companies by offering a more targeted and cost-effective way to introduce physicians to new and existing drugs.**The company has ridden its first-mover advantage to an 80% market share that reaches 45% of all U.S. physicians, and it benefits from a recurring revenue base to fund R&D for new products.
Growth potential of a medical/pharmaceutical data management company that has innovated electronic media platforms that facilitate physician, nurse, pharmacist capabilities
Fundamentals and monetization questions be damned - expect market frothiness over anything that can combine healthcare, information management and mobile devices, for a while at least.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions